AKCEA-TTR-LRx

Drug Profile

AKCEA-TTR-LRx

Alternative Names: IONIS-TTR-LRx

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ionis Pharmaceuticals
  • Class Antisense oligonucleotides
  • Mechanism of Action Antisense RNA modulators; Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Amyloidosis

Most Recent Events

  • 06 Aug 2018 Ionis Pharmaceuticals and Akcea Therapeutics plan phase I trials for Amyloidosis in 2018
  • 09 May 2018 Akcea Therapeutics plan phase I trials of AKCEA-TTR-LRx in 2018
  • 15 Mar 2018 AKCEA-TTR-LRx licensed to Akcea Therapeutics, worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top